A patient presented with symptoms of peripheral neuropathy and macrocytic anemia. She was given folate 5mg and the blood picture improved. However, the neurologic manifestations were aggravated. What is the most likely cause?

Explanation

## Correct Answer: C. Folate therapy using the B12 stores This question tests understanding of the **methyl-trap hypothesis** and the critical interplay between folate and B12 metabolism. The patient presented with both macrocytic anemia and peripheral neuropathy—a classic dual presentation of B12 deficiency. When folate 5 mg was administered, the anemia improved (because folate can partially bypass the B12 block in DNA synthesis), but neurologic symptoms worsened. This paradoxical deterioration is the key discriminator. The mechanism: B12 deficiency causes accumulation of methyltetrahydrofolate (methylTHF) because B12 is required for the methionine synthase reaction that converts methylTHF back to THF. When high-dose folate is given, it temporarily "rescues" DNA synthesis by providing alternative one-carbon donors, allowing RBC production to resume and anemia to improve. However, this masks the underlying B12 deficiency and allows continued depletion of B12 stores. Since B12 is essential for myelin synthesis and neurologic function, the neurologic manifestations—which depend on B12 for maintenance of myelin—progressively deteriorate as B12 stores are consumed without replacement. This is why folate monotherapy in B12 deficiency is dangerous: it treats the hematologic manifestation while allowing neurologic damage to progress unchecked. The correct answer reflects that folate therapy is "using up" the remaining B12 stores without addressing the underlying B12 deficiency, leading to neurologic worsening. ## Why the other options are wrong **A. Treatment with folate unmasking pyridoxine deficiency** — This is wrong because pyridoxine (B6) deficiency causes peripheral neuropathy but does NOT cause macrocytic anemia—it causes microcytic or normocytic anemia. The initial presentation of macrocytic anemia + neuropathy is pathognomonic for B12 deficiency, not B6 deficiency. Folate does not unmask B6 deficiency; this is a distractor that confuses vitamin interactions. **B. Deficiency of folate reductase in CNS** — This is wrong because folate reductase deficiency is an extremely rare genetic disorder that would present with neurologic symptoms from birth/infancy, not in an adult with acquired macrocytic anemia. The clinical scenario describes an acquired condition responding to folate (anemia improved), which rules out a primary enzyme deficiency. This is a distractor using obscure biochemistry. **D. Malabsorption of folate** — This is wrong because the patient's anemia improved after folate supplementation, proving that folate absorption is intact. If folate malabsorption were the problem, oral folate would not have improved the blood picture. The worsening of neurologic symptoms after folate therapy is the critical clue that points to B12 depletion, not folate malabsorption. ## High-Yield Facts - **Methyl-trap hypothesis**: B12 deficiency causes methylTHF accumulation because B12 is required for methionine synthase; folate therapy bypasses this block but masks B12 deficiency. - **Folate monotherapy in B12 deficiency is contraindicated** because it improves anemia while allowing neurologic deterioration—a dangerous masking effect. - **B12 deficiency presents with both hematologic (macrocytic anemia) and neurologic (peripheral neuropathy, subacute combined degeneration) manifestations** that must be treated together. - **Neurologic manifestations of B12 deficiency are irreversible if prolonged**; they depend on B12 for myelin synthesis and cannot be rescued by folate alone. - **High-dose folate (5 mg) in undiagnosed B12 deficiency accelerates neurologic damage** by consuming remaining B12 stores through increased one-carbon metabolism. ## Mnemonics **FOLATE TRAP in B12 deficiency** **F**olate improves **A**nemia but **L**eaves **A**xons damaged; **T**herapy **R**equires **A**ddressing **P**rimary B12 deficiency, **E**lse neurologic damage is irreversible. **B12 NEURO rule** **B**12 deficiency → **N**eurologic damage is **E**xacerbated by folate monotherapy; **U**nderstanding the **R**ole of B12 in myelin is **O**bligatory. ## NBE Trap NBE pairs "folate improves anemia" with "so folate is the answer" to trap students who don't recognize the methyl-trap hypothesis. The worsening of neurologic symptoms is the critical clue that folate is masking B12 deficiency, not treating it. ## Clinical Pearl In Indian clinical practice, many patients with B12 deficiency (common due to vegetarian diet and pernicious anemia) are empirically given folate without B12 testing. This is a critical error: the anemia may improve temporarily, but the patient develops irreversible subacute combined degeneration. Always measure B12 and methylmalonic acid before starting folate in macrocytic anemia with neurologic symptoms. _Reference: Harrison Ch. 100 (Megaloblastic Anemias); KD Tripathi Ch. 32 (Water-Soluble Vitamins); Robbins Ch. 14 (Red Blood Cell Disorders)_